The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
Vaccine makers such as Pfizer are breathing easier now that the Supreme Court has ruled they can’t be sued for defective vaccine designs. The majority opinion by Justice Antonin Scalia was unequivocal: Congress has barred lawsu…
Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren’t drugs at all, from smartphone apps and educational websites to social media platforms and…
From October 2010 to February 2011, biotech Clinical Data’s stock doubled, mostly thanks to FDA approval of its novel antidepressant. But also pushing the stock up — and making it likely to perhaps double again — is speculati…
Companies that have piled up cash over the past few years are finding one good use for it: Repurchasing their own shares. January alone saw $57 billion in buybacks, compared with $357 billion for all of 2010. While buybacks don…